alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 31.2

                           Section 302 Certifications

I, Marc Casavant, certify that:

         1.       I have reviewed this quarterly report on form 10-QSB of Laredo
                  Investment Corp.

         2.       Based on my knowledge,  this quarterly report does not contain
                  any untrue  statement  of a  material  fact or omit to state a
                  material fact necessary to make the statements  made, in light
                  of the  circumstances  under which such  statements were made,
                  not  misleading  with  respect to the  period  covered by this
                  quarterly report.

         3.       Based on my  knowledge,  the financial  statements,  and other
                  financial  information  included  in  this  quarterly  report,
                  fairly   present  in  all  material   respects  the  financial
                  condition,  results  of  operations  and  cash  flows  of  the
                  registrant  as of,  and for,  the  periods  presented  in this
                  quarterly report;

         4.       I am responsible for establishing  and maintaining  disclosure
                  controls  and  procedures  (as defined in  Exchange  Act Rules
                  13a-14 and 15d-14) for the registrant and have:

         a)       Designed  such  disclosure  controls and  procedures to ensure
                  that  material   information   relating  to  the   registrant,
                  including its consolidated  subsidiaries,  is made known to us
                  by others  within  those  entities,  particularly  during  the
                  period in which this quarterly report is being prepared.

         b)       Evaluated the  effectiveness  of the  registrant's  disclosure
                  controls and  procedures  as of a date within 90 days prior to
                  the filing  date of this  quarterly  report  (the  "Evaluation
                  Date"); and

         c)       Presented in this quarterly  report our conclusions  about the
                  effectiveness of the disclosure  controls and procedures based
                  on our evaluation as of the Evaluation Date;

         5.       I have disclosed,  based on our most recent evaluation, to the
                  registrant's  auditors and the audit committee of registrant's
                  board of  directors  (or  persons  performing  the  equivalent
                  functions):

         a)       All  significant  deficiencies  in the design or  operation of
                  internal   controls   which   could   adversely   affect   the
                  registrant's ability to record, process,  summarize and report
                  financial  data  and  have  identified  for  the  registrant's
                  auditors any material weaknesses in internal controls; and

         b)       Any fraud,  whether or not material,  that involves management
                  or  other  employees  who  have  a  significant  role  in  the
                  registrant's internal controls; and

Date:  August 14, 2003

By: /s/ Marc Casavant
Marc Casavant, CFO, Director
EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT BY
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection  with the Quarterly  Report of GFR  Pharmaceuticals,  Inc. on Form
10-QSB for the period  ending June 30, 2006,  as filed with the  Securities  and
Exchange Commission on the date hereof (the "Report"),  I, Richard Pierce, Chief
Executive Officer of the Company,  certify,  pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the  Sarbanes-Oxley  Act of 2002, that, to
the best of my knowledge and belief:

         (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) The  information  contained in the Report fairly  presents,  in all
material  respects,  the  financial  condition  and result of  operations of the
Company.



By: /s/ Richard Pierce
Richard Pierce
CEO, Director
(Principal Executive Officer)

Date: August 23, 2006

A signed  original of this written  statement  required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the  electronic  version of this written  statement
has been  provided  to the  Company  and will be  retained  by the  Company  and
furnished to the Securities and Exchange Commission or its staff upon request.
[Federal Register Volume 74, Number 75 (Tuesday, April 21, 2009)]
[Notices]
[Page 18248]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-9215]


=======================================================================
-----------------------------------------------------------------------

INTER-AMERICAN FOUNDATION BOARD


Inter-American Foundation Board Meeting; Sunshine Act Meetings

Time and Date: April 27, 2009, 9 a.m.-1 p.m.

Place: 901 N. Stuart Street, Tenth Floor, Arlington, Virginia 22203.

Status: Open to the public.

Matters to be Considered:
    <bullet> Approval of the Minutes of the December 15, 2008, Meeting 
of the Board of Directors
    <bullet> President's Report
    <bullet> Regional and Summit of the Americas Overview
    <bullet> Congressional Affairs
    <bullet> IAF Program Activities
    <bullet> RedEAmerica
    <bullet> Operations
    <bullet> IAF Advisory Council
    <bullet> Board Site Visit

Portions to be Open to the Public:
    <bullet> Approval of the Minutes of the December 15, 2008, Meeting 
of the Board of Directors
    <bullet> President's Report
    <bullet> Regional and Summit of the Americas Overview
    <bullet> Congressional Affairs
    <bullet> IAF Program Activities
    <bullet> RedEAmerica
    <bullet> Operations
    <bullet> IAF Advisory Council
    <bullet> Board Site Visit

FOR FURTHER INFORMATION CONTACT: Jennifer Hodges Reynolds, General 
Counsel, (703) 306-4301.

    Dated: April 13, 2009.
Jennifer Hodges Reynolds,
General Counsel.
[FR Doc. E9-9215 Filed 4-17-09; 4:15 pm]
BILLING CODE 7025-01-P
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 2802 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 2802

  To suspend temporarily the duty on benzenesulfonic acid, 4-chloro-2-
 [[4,5-dihydro-3-methyl-5-oxo-1-(3-sulfophenyl)-1H-pyrazol-4-yl]azo]-5-
                         methyl-, calcium salt.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 7, 2012

   Mr. Kerry introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
  To suspend temporarily the duty on benzenesulfonic acid, 4-chloro-2-
 [[4,5-dihydro-3-methyl-5-oxo-1-(3-sulfophenyl)-1H-pyrazol-4-yl]azo]-5-
                         methyl-, calcium salt.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. BENZENESULFONIC ACID, 4-CHLORO-2-[[4,5-DIHYDRO-3-METHYL-5-
              OXO-1-(3-SULFOPHENYL)-1H-PYRAZOL-4-YL]AZO]-5-METHYL-, 
              CALCIUM SALT.

    (a) In General.--Subchapter II of chapter 99 of the Harmonized 
Tariff Schedule of the United States is amended by inserting in 
numerical sequence the following new heading:

``     9902.01.00      Benzenesulfonic     Free         No change        No change        On or before 12/  ''.
                        acid, 4-chloro-2-                                                  31/2015.......
                        [[4,5-dihydro-3-
                        methyl-5-oxo-1-(3-
                        sulfophenyl)-1H-
                        pyrazol-4-yl]azo]-
                        5-methyl-,
                        calcium salt
                        (1:1) (CAS No.
                        129423-54-7)
                        (provided for in
                        subheading
                        3204.17.60)......

    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 307 Introduced in Senate (IS)]

112th CONGRESS
  1st Session
                                 S. 307

To designate the Federal building and United States courthouse located 
at 217 West King Street, Martinsburg, West Virginia, as the ``W. Craig 
      Broadwater Federal Building and United States Courthouse''.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            February 8, 2011

Mr. Rockefeller introduced the following bill; which was read twice and 
       referred to the Committee on Environment and Public Works

_______________________________________________________________________

                                 A BILL

 
To designate the Federal building and United States courthouse located 
at 217 West King Street, Martinsburg, West Virginia, as the ``W. Craig 
      Broadwater Federal Building and United States Courthouse''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. DESIGNATION.

    The Federal building and United States courthouse located at 217 
West King Street, Martinsburg, West Virginia, shall be known and 
designated as the ``W. Craig Broadwater Federal Building and United 
States Courthouse''.

SEC. 2. REFERENCES.

    Any reference in a law, map, regulation, document, paper, or other 
record of the United States to the Federal building and United States 
courthouse referred to in section 1 shall be deemed to be a reference 
to the ``W. Craig Broadwater Federal Building and United States 
Courthouse''.
                                 <all>
```
## In The Court of Appeals Seventh District of Texas at Amarillo

No. 07
- 15
- 00101
- CV

IN RE LUIS S. LAGAIT E, JR., RELATOR
OPINION ON ORIGINAL PROCEEDING FOR WRIT OF MANDAMUS April 9, 2015 

### MEMORANDUM OPINION Before QUINN, C.J., and CAMPBELL and HANCOCK, JJ. Pending before the court is the petition for writ of mandamus filed by Luis S. Lagaite, Jr

. He asks us to order Respondent, “William Stephen , in his individual and official capacity as executive director of T.D.C.” t o “ immediately assigned [sic] relator to a permanent ID

. Unit, and the return of all his legal and personal property, so he can perfect an appeal.” We deny the petition. We cannot normally issue a writ of mandamus against anyone other than a judge. T EX

. G OV ’ T C ODE A NN . § 22.221 ( West 2004). There exists an exception to that limitation, however. It encompasses instances wherein mandamus is necessary to protect our appellate juris diction. In re Washington, 7 S.W.3d 181, 182 (Tex. App.

— Houston [1st Dist.] 1999, no pet.). But, before it can be said that we are protecting our2

appellate jurisdiction, there must be an appeal pending wherein the relator is a party. Id. Lagaite’s com plaint does not relate to a pending appeal or to our jurisdiction over a pending appeal. Nor has he appended a copy of any judgment susceptible to appeal. More importantly, we read his application as simply his complaint about having a temporary prison a ssignment and as a means of securing a permanent prison assignment. We have no jurisdiction to require the executive director of the “T.D.C.” to make such an assignment. Accordingly, the petition for mandamus is denied.

Per Curia m
July 14, 2015

US Department of Transportation

Docket Management System

1200 New Jersey Ave, SE

Washington, DC, 20590

To Whom It May Concern:

The Nature Coast Business Development Council of Levy County, Fla, supports the exemption request for

Section 333 of the Federal Aviation Administration Reform Act 2012, filed by DeBerry Marketing Services,

LLC.

As the FAA continues to develop a plan to integrate Unmanned Aerial Systems with general aviation, our

organization stands ready to support the use of such aircraft. With a large rural county comprised of

thousands of acres of forests, agricultural lands and waterways, we embrace the advantages and

opportunities such technologies present.

Commercial use of UAS is looked at as a desired industry in Levy County because of its ability to strengthen

supply chains and foster greater economic development. One of our greatest industries remains eco

‐ tourism

with close to a million tourists visiting our springs, trails and waterways. Using UAS for promotional purposes

– such as aerial photography and video

– can provide a virtual tour for anyone interested in visiting or

returning to the region, helping chambers of commerce, tourist development councils, communities and our

organization attract greater numbers or visitors, with the potential for job creation and more home sales.

Through the granting of a petition, we believe the petitioner could not only improve these efforts, but

increase awareness of the benefits of UAS use to film natural resources. We offer our support and are

hopeful of your approval of the request.

Sincerely,

David Pieklik

Executive Director 109 NW 3RD AVE, CHIEFLAND, FL 32626

352

‐ 493

‐ 6797 ▪ director@naturecoast.org ▪ www.naturecoast.org
Exhibit 32

                Certifications Pursuant to 18 U.S.C. Section 1350

         The  undersigned,  who are the chief  executive  officer  and the chief
financial  officer of Cornerstone  Bancorp,  each hereby  certifies that, to the
best of his/her  knowledge,  the  accompanying  Form 10-KSB of the issuer  fully
complies  with the  requirements  of  Section  13(a)or  15(d) of the  Securities
Exchange  Act of 1934,  and that  information  contained  in the  report  fairly
presents,  in all material  respects,  the  financial  condition  and results of
operations of the issuer.

March 18, 2005

                                  s/J. Rodger Anthony
                                  ----------------------------------------------
                                  J. Rodger Anthony
                                  Chief Executive Officer


                                  s/Jennifer M. Champagne
                                  ----------------------------------------------
                                  Jennifer M. Champagne
                                  Chief Financial Officer
Huebler, 128 Nev. „ 275 P.3d 91, 96 (2012), cert. denied, 568 U.S. 

, 133 S. Ct. 988 (2013). Accordingly, we 

ORDER the judgment of conviction AFFIRMED. 

f\4J4 LE 

Hardesty 

cc: Hon. Michael Montero, District Judge 

Humboldt County Public Defender 

Attorney General/Carson City 

Humboldt County District Attorney 

Humboldt County Clerk 

J. 

SUPREME COURT 

OF 

NEVADA 

(0) 1947A 

2
# Official Journal C 124I/2020

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 124I |
| | |
| English edition | Information and Notices | Volume 6317 April 2020 |

ISSN 1977-091X

Official Journal

of the European Union

C 124I

English edition

Information and Notices

Volume 6317 April 2020

---

| Contents | page |
| --- | --- |
| | II   Information |
| | INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2020/C 124 I/01 | Communication from the Commission — Guidance on Apps supporting the fight against COVID 19 pandemic in relation to data protection | 1 |

Contents

page

II   Information

INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2020/C 124 I/01

Communication from the Commission — Guidance on Apps supporting the fight against COVID 19 pandemic in relation to data protection

1

---

| EN | |
| --- | --- |

EN
COURT OF APPEALS

SECOND DISTRICT OF TEXAS

FORT WORTH

NO. 02-13-00435-CV

Henry M. Porter, Jr. and James 

Harold Porter

v.

Wise County, Texas

§

§

§

§

From the 271st District Court

of Wise County (07-07-565)

February 20, 2014

Per Curiam

JUDGMENT

This court has considered the record on appeal in this case and holds that 

the appeal should be dismissed. It is ordered that the appeal is dismissed for 

want of jurisdiction.

SECOND DISTRICT COURT OF APPEALS 

PER CURIAM
DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA

FOURTH DISTRICT

KATHLEEN M. WEISS a/k/a

KATHLEEN M. WEISS O'NEIL, 

Appellant,

v.

HSBC BANK USA, NATIONAL ASSOCIATION, AS TRUSTEE FOR 

NOMURA ASSET ACCEPTANCE CORPORATION MORTGAGE PASSTHROUGH CERTIFICATES, SERIES 2005-AR4, WELLS FARGO BANK, 

N.A., S/B/M WACHOVIA BANK, N.A., SUNSET LAKES MASTER 

ASSOCIATION, INC., 

Appellees.

No. 4D17-1212 

[June 6, 2018]

Appeal from the Circuit Court for the Seventeenth Judicial Circuit, 

Broward County; Barry J. Stone, Senior Judge; L.T. Case No. CACE12-

20713 (11).

Jonathan Kline of Jonathan Kline, P.A., Weston, for appellant.

Karusha Y. Sharp, and M. Hope Keating of Greenberg Traurig, P.A., 

Tallahassee; and Michele L. Stocker of Greenberg Traurig, P.A., Fort 

Lauderdale, for appellee HSBC Bank USA, National Association, as Trustee 

for Nomura Asset Acceptance Corporation Mortgage Pass-through 

Certificates, Series 2005-AR4.

PER CURIAM.

Affirmed. See Bolus v. U.S. Bank Nat’l Ass’n, 210 So. 3d 691 (Fla. 4th

DCA 2014). 

WARNER, TAYLOR, and LEVINE, JJ., concur. 

* * *

Not final until disposition of timely filed motion for rehearing.
Unassociated Document


Exhibit 10.1







Shengtai Pharmaceutical, Inc.


November 1, 2011


Tao Jin


10th Floor, China World Tower (Phase III)


No.1 Jianguo Menwai Avenue


Beijing 100004, China


 


Dear Tao Jin:


 


On behalf of the Board of Directors of Shengtai Pharmaceutical, Inc. (the “Company”), it is my pleasure to extend you an offer to become a member of the Board of Director of the Company. Speaking for myself, as well as the other members of the Company’s Board and management team, we all look forward to working with you.


 


The Company will expect that, as a member of the Board of Directors, you participate in person or by phone in substantially all of the Board’s regularly scheduled meeting as well as the meetings of Board committees to which you are appointed .We request that you attend in person as many meetings as possible. The Board meetings are generally held at the Company’s offices in Changda Road East, Development District, Changle County, Shandong, China. Additionally, the Company is extending you this offer in the expectation that the Board of Directors will appoint you as Chairman of the Compensation Committee and a member of the Audit Committee and the Nominating Committee.


 


If you choose to accept our offer, you are entitled to an annual director’s fee of US$30,000, or its RMB equivalent, as applicable, less payroll deductions and all required withholdings, if any. Your annual fee will be payable quarterly. You are recommended to seek professional advice on whether the amount of any remuneration payable to you as directors of the Company is subject to US or New York tax and if so, to include the details of such remuneration in your tax returns.


 


Should you choose to accept our offer, I anticipate that your appointment as a Director will be approved by a consent signed by the Board of Directors. Your appointment to the Board is initially for a term of 12 months from the date you accept this offer, or until the next annual shareholder meeting, or until your successor has been duly appointed or elected, whichever is the earlier, but both you and the Board can terminate this appointment at will during your appointment period.


 


We look forward to working with you to make Shengtai Pharmaceutical, Inc. a great success. To indicate your acceptance of the Company’s offer, please sign and date this letter in the space provided below and return it to me.


 




	 	Very truly yours,	 
	 	 	 
	 	SHENGTAI PHARMACEUTICAL, INC.	 
	 	 	 
	 	 
By: /s/Qingtai Liu


Qingtai Liu


Chairman of the Board of Direcors

	 







 


ACCEPTED AND AGREED:


 


Tao Jin


 


/s/ Tao Jin


Signature







November 1, 2011


Date
Exhibit 32.2   CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002   In connection with the Annual Report of United Bancshares, Inc. (the "Corporation") on Form 10-K for the period ending December 31, 2008, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Brian D. Young, Chief Financial Officer, certify, pursuant to 18 U.S.C. §  1350, as adopted pursuant to §  906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:   (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Corporation.     /s/ Brian D. Young Brian D. Young Chief Financial Officer   Date: March 20, 2009  *This certification is being furnished as required by Rule 13a 14(b) under the Securities Exchange Act of 1934 (the Exchange Act) and Section 1350 of Chapter 63 of Title 18 of the United States Code, and shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section.  This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise stated in such filing.
II 

112TH CONGRESS 

2D SESSION S. 3057 

To suspend temporarily the duty on certain leathered footwear for women. 

IN THE SENATE OF THE UNITED STATES 

MAY 9, 2012 

Mr. WYDEN introduced the following bill; which was read twice and referred 

to the Committee on Finance 

A BILL 

To suspend temporarily the duty on certain leathered 

footwear for women. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. CERTAIN LEATHERED FOOTWEAR FOR WOMEN. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading: 


tjames on DSK6SPTVN1PROD with BILLS
2 

•S 3057 IS

‘‘ 9902.01.00 Footwear for women, with 

uppers of leather other than 

of pigskin (other than house 

slippers, work footwear, tennis shoes, basketball shoes, 

gym shoes, training shoes 

and the like, and other than 

slip-on footwear), valued $27/ 

pair or higher, such footwear 

which designed to be worn in 

lieu of, but not over, other 

footwear as a protection 

against water, oil, grease or 

chemicals or cold or inclement weather where such protection includes protection 

against water that is imparted by the use of a coated 

or laminated textile fabric 

(provided for in subheading 

6403.99.90) ........................... Free No change No change On or before 

12/31/2015 ’’. 

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies with respect to goods entered, or 

3 withdrawn from warehouse for consumption, on or after 

4 the 15th day after the date of the enactment of this Act. 

Æ 


tjames on DSK6SPTVN1PROD with BILLS